AstraZeneca (AZNCF) News Today $160.14 -0.40 (-0.25%) As of 02:25 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartDividendFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock AZNCF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period AstraZeneca (LSE:AZN) Announces Positive Phase III Trial Results For Lung Cancer TreatmentSeptember 8 at 11:18 PM | finance.yahoo.comAstraZeneca says Tagrisso and chemotherapy deliver survival benefitsSeptember 7 at 11:38 PM | lse.co.ukAstraZeneca's lung cancer combination boosted survival in key studySeptember 7 at 5:18 AM | msn.comAstraZeneca announces Rs 176 crore investment to expand Global Innovation & Technology Centre in ChennaiSeptember 6, 2025 | msn.comAstraZeneca Announces Current Share Capital and Voting RightsSeptember 6, 2025 | theglobeandmail.comAstraZeneca's (LON:AZN) investors will be pleased with their notable 61% return over the last five yearsSeptember 6, 2025 | finance.yahoo.comBerenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)September 2, 2025 | theglobeandmail.comAstraZeneca’s baxdrostat shows promise in Phase III hypertension trialSeptember 1, 2025 | finance.yahoo.comAstraZeneca bounces back from scandal in ChinaAugust 27, 2025 | ft.comAstraZeneca to build pharma innovation hub in PhilippinesAugust 26, 2025 | msn.comDaiichi Sankyo and AstraZeneca’s Datroway receives approval in ChinaAugust 25, 2025 | msn.comAstraZeneca’s New Asthma Study: Potential Market ImpactAugust 22, 2025 | msn.comAstraZeneca’s Innovative Lung Cancer Screening Study: A Game Changer for Early DetectionAugust 22, 2025 | msn.comAstraZeneca (LSE:AZN) Joins Forces To Launch Sovereign AI Supercomputer With Sferical AIAugust 22, 2025 | finance.yahoo.comAstraZeneca Vietnam office in Hanoi receives LEED Gold certificationAugust 22, 2025 | msn.comPEZA, AstraZeneca partner to boost pharma investments in PHAugust 21, 2025 | msn.comDTI, AstraZeneca to develop Pharma Innovation HubAugust 20, 2025 | msn.comAstraZeneca to build Philippines’ first pharma innovation hubAugust 19, 2025 | msn.comScared of needles? AstraZeneca launches FluMist Home nasal spray deliveryAugust 17, 2025 | msn.comAstraZeneca’s Anifrolumab Pregnancy Study: A New Chapter in SLE TreatmentAugust 16, 2025 | theglobeandmail.comAstraZeneca’s CAR-T Therapy Study: A New Hope for Hepatocellular CarcinomaAugust 16, 2025 | msn.comAstraZeneca launches at-home FluMist nasal spray deliveryAugust 15, 2025 | abcnews.go.comAmgen and AstraZeneca’s New Study on Tarlatamab for Lung Cancer: Key Insights for InvestorsAugust 15, 2025 | theglobeandmail.comAstraZeneca’s CRT Study in Russia: Implications for Lung Cancer TreatmentAugust 13, 2025 | msn.comSolid Earnings Reflect AstraZeneca's (LON:AZN) Strength As A BusinessAugust 9, 2025 | finance.yahoo.comBritain is squeezing AstraZeneca too tightAugust 8, 2025 | ft.comAstraZeneca’s Phase 1 Study on AZD9833: A New Hope for Advanced Breast CancerAugust 8, 2025 | msn.comInside AstraZeneca’s long-game strategy in lung cancerAugust 7, 2025 | finance.yahoo.comAstraZeneca’s New Trial: A Potential Breakthrough for Eosinophilic Diseases in ChildrenAugust 7, 2025 | msn.comAstraZeneca slips Wednesday, underperforms marketAugust 6, 2025 | marketwatch.comAstraZeneca’s New Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer TreatmentAugust 6, 2025 | msn.comUBS Reaffirms Their Buy Rating on AstraZeneca (AZN)August 6, 2025 | theglobeandmail.comAstraZeneca’s Innovative Propellant Study: Market Implications and Future ProspectsJuly 31, 2025 | msn.comAstraZeneca’s PHRASE-HF Study: A Game Changer in Heart Failure Treatment?July 31, 2025 | msn.comWhy AstraZeneca Stock Was Topping the Market on TuesdayJuly 30, 2025 | msn.comAstraZeneca Just Missed Estimates, but Here’s Why Bulls Aren’t Worried YetJuly 30, 2025 | msn.comStock Movers: AstraZeneca, Philips, StellantisJuly 29, 2025 | bloomberg.comAstraZeneca beats profit expectations on robust drug sales, U.S. demandJuly 29, 2025 | msn.comAstraZeneca seeks US drug price cuts amid expansion plans, strong demandJuly 29, 2025 | msn.comLONDON BRIEFING: AstraZeneca earnings increase; Greggs profit sinksJuly 29, 2025 | lse.co.ukAstraZeneca beats forecasts after record US growthJuly 29, 2025 | ft.comAstraZeneca trumps Q2 forecasts, keeps outlook amid pricing, trade pressuresJuly 29, 2025 | za.investing.comAstraZeneca Quarterly Net Profit Jumps On Record US GrowthJuly 29, 2025 | barrons.comAstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of GefurulimabJuly 29, 2025 | msn.comAstraZeneca second quarter sales and profit boosted by cancer drugsJuly 29, 2025 | lse.co.ukAstraZeneca Profit, Revenue Lifted by Cancer DrugsJuly 29, 2025 | bloomberg.comAstraZeneca's Imfinzi granted priority review for cancer forms in USJuly 28, 2025 | lse.co.ukAstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on InnovationJuly 26, 2025 | msn.comAstraZeneca Expected to Post Higher Core EPS, Total Revenue -- Earnings PreviewJuly 25, 2025 | marketwatch.comAstraZeneca (LSE:AZN) Showcases Promising Results For Gefurulimab In Global Myasthenia Gravis StudyJuly 25, 2025 | finance.yahoo.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZNCF Media Mentions By Week AZNCF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZNCF News Sentiment▼0.310.84▲Average Medical News Sentiment AZNCF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZNCF Articles This Week▼66▲AZNCF Articles Average Week Get the Latest News and Ratings for AZNCF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies 4Front Ventures News Today Ainos News Today Algernon Pharmaceuticals News Today Allstar Health Brands News Today AVAX Technologies News Today BriaCell Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AZNCF) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersThis stock just surpassed PalantirThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemTucked away outside San Antonio sits a facility most Americans don’t know exists. It’s not mining gold or o...True Market Insiders | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AZNCF Stock Alerts